[1]张梦娜,李文生.髓过氧化物酶在淋巴造血系统疾病表达的最新研究进展[J].现代检验医学杂志,2022,37(02):195-198.[doi:10.3969/j.issn.1671-7414.2022.02.039]
　ZHANG Meng-na,LI Wen-sheng.Recent Research Progress of Myeloperoxidase Expression in Lymphatic Hematopoietic Diseases[J].Journal of Modern Laboratory Medicine,2022,37(02):195-198.[doi:10.3969/j.issn.1671-7414.2022.02.039]
点击复制

髓过氧化物酶在淋巴造血系统疾病表达的最新研究进展()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
195-198
栏目:
综　述
出版日期:
2022-03-15

文章信息/Info

Title:
Recent Research Progress of Myeloperoxidase Expression in Lymphatic Hematopoietic Diseases
文章编号:
1671-7414（2022）02-195-04
作者:
张梦娜1; 李文生2
（1.西安医学院，西安710021；2.陕西省人民医院病理科，西安710068)
Author(s):
ZHANG Meng-na1;  LI Wen-sheng2
(1.Xi’an Medical University, Xi’an 710021, China;2.Department of Pathology,Shaanxi Provincial People’s Hospital, Xi’an 710068 , China)
关键词:
髓过氧化物酶; 淋巴造血疾病; 急性髓系白血病; 组织细胞坏死性淋巴结炎
分类号:
R446.8
DOI:
10.3969/j.issn.1671-7414.2022.02.039
文献标志码:
A
摘要:
髓过氧化物酶(myeloperoxidase，MPO) 是一种血红素蛋白，存在于髓系细胞( 主要是中性粒细胞和单核细胞)的嗜天青颗粒中，是髓系细胞的特异性标志，在宿主防御感染中起重要作用。近年来研究发现，MPO 不仅表达于急性髓系白血病，还可表达于淋巴造血系统中其他疾病，例如慢性粒细胞白血病、骨髓增生异常综合征、髓系肉瘤、急性淋巴细胞白血病、淋巴母细胞性淋巴瘤、组织细胞坏死性淋巴结炎等。该文主要阐述MPO 在淋巴造血系统疾病中的表达，探讨其在疾病诊断和鉴别诊断中的意义。
Abstract:
Myeloperoxidase (MPO) is a hemeprotein that exists in the azurophilic granules of myeloid cells (mainly neutrophils and monocytes). It is a specific marker of myeloid cells and plays an important role in host defense against infection.Recent studies have found that MPO is not only expressed in acute myeloid leukemia, but also in other diseases of the lymphatic hematopoietic system, such as chronic myeloid leukemia, myelodysplastic syndrome, myeloid sarcoma, acute lymphoblastic leukemia, lymphoblastic lymphoma，histiocytic necrotizing lymphadenitis, etc. This article mainly expounds the expression of MPO in lymphatic hematopoietic diseases, and discusses its significance in disease diagnosis and differential diagnosis.

参考文献/References:

[1] ABDO A I, RAYNER B S, VAN REYK D M, et al.Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction[J].Redox Biol,2017,13:623-632.
[2] GARAI D, R?OS-GONZ?LEZ B B, FURTM?LLER P G, et al.Mechanisms of myeloperoxidase catalyzed oxidation of H2S by H2O2 or O2 to produce potent protein Cys-polysulfide-inducing species[J]. Free Radic Biol Med, 2017,113:551-563.
[3] ABDOU A G, SSLEIT I, BAKRY O A, et al.Leukemia cutis from CD56 positive, myeloperoxidase negative acute myeloid leukemia[J].Acta Dermatovenerol Croat,2013,21(3):189-192.
[4] 时小淋, 王晓丰, 刘鹏, 等. 中性粒细胞杀菌机理 的最新研究进展[J]. 现代检验医学杂志, 2020, 35 (1):161-164. SHI Xiaolin, WANG Xiaofeng, LIU Peng, et al. Recent research progress on germicidal mechanism of neutrophils[J].Journal of Modern Laboratory Medicine,2020,35(1):161-164.
[5] 尚磊, 陈雪晶, 李元媛, 等.502 例急性髓系白血病 患者髓过氧化物酶的表达及其在分型诊断中的意义 [J]. 中华血液学杂志,2015,36(11):906-911. SHANG Lei,CHEN Xuejing,LI Yuanyuan, et al. Expression of cMPO in 502 cases of acute myeloid leukemia（AML）and its diagnosis significance in AML subtypes [J]. Chinese Journal of Hematology,2015,36(11):906-911.
[6] ITONAGA H, IMANISHI D, WONG Y F, et al.Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation o f DNA m e t h y l t r a n s f e r a s e DNMT 3 B [ J ] . Leukemia,2014,28(7):1459-1466.
[7] BRAS A E, OSMANI Z, DE HAAS V, et al.Standardised immunophenotypic analysis of myeloperoxidase in acute leukemia[J].Br J Haematol, 2021,193(5):922-927.
[8] 韩秀蕊, 杨娣娣, 王九菊, 等.136 例急性白血病 免疫表型特点及临床意义[J]. 现代检验医学杂 志,2014,29(4):91-93. HAN Xiurui, YANG Didi, WANG Jiuju, et a1.Immunophenotype characteristics and clinical significance of 136 patients with acute leukemia[J]. Journal of Modern Laboratory Medicine, 2014,29(4):91-93.
[9] TOMINAGA-SATO S. TSUSHIMA H, ANDO K, et a1.Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts[J].Int J Hematol,2011,94(1):81-89.
[10] KAMIJO R, ITONAGA H, KIHARA R, et a1.Distinct gene alterations with a high percentage of myeloperoxidase- positive leukemic blasts in de novo acute myeloid leukemia[J].Leuk Res,2018,65:34-41.
[11] 董晓燕, 李玉龙, 姜丽, 等. 髓过氧化物酶表达与急 性髓系白血病基因突变和预后的相关性研究[J]. 中 华血液学杂志,2019,40(1)40-45. DONG Xiaoyan,LI Yulong,JIANG Li, et al. Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia [J]. Chinese Journal of Hematology,2019,40(1):40-45.
[12] 曹旭东, 孙续国, 宋敬敬, 等. 微流控芯片单细胞分 析慢性粒细胞白血病患者粒细胞表达髓过氧化物酶 [J]. 天津医科大学学报,2014,20(2):157-158. CAO Xudong,SUN Xuguo,SONG Jingjing, et al.Analysis of myeloperoxidase expression in granulocytes of patients with chronic myelogenous leukemia by single cell microfluidic chip[J]. Journal of Tianjin Medical University, 2014,20(2):157-158.
[13] ANAND M, GHARA N, KUMAR R, et al. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia[J].Ann Hematol,2005,84(12):767-770.
[14] STEINER M, ATTARBASCHI A, DWORZAK M, et al.Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia[J].J Pediatr Hematol Oncol,2010,32(1):e4-e7.
[15] MCGINNIS E, YANG D, AU N, et al.Clinical and laboratory features associated with myeloperoxidase expression in pediatric B-lymphoblastic leukemia[J]. Cytometry B Clin Cytom,2020,100(4):446-453.
[16] 陈枫煜, 裴强, 王启, 等. 以骨髓增殖性肿瘤为首发 表现的T 淋巴母细胞淋巴瘤合并急性髓系白血病 1 例并文献复习[J]. 重庆医学, 2020, 49(14):2373- 2376, 2379. CHEN Fengyu,PEI Q iang,WANG Qi, e t a l . Myeloproliferative neoplasm as the first manifestation in T-lymphoblastic lymphoma with progression to acute myelocytic leukemia: a case report and literature review [J].Chongqing Medicine, 2020,49(14):2373- 2376, 2379.
[17] 张景航, 高子芬, 颜野, 等. 淋巴母细胞淋巴瘤105 例临床病理学特点[J]. 白血病·淋巴瘤, 2012, 21(11): 650-653. ZHANG Jinghang, GAO Zifen, YAN Ye, et al. Clinicopathological study of 105 lymphoblastic lymphoma cases[J]. Journal of Leukemia and Lymphoma,2012,21(11):650-653.
[18] SUGGS J L, CRUSE J M, LEWIS R E.Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias[J].Exp Mol Pathol,2007,83(3):471-473.
[19] DUNPHY C H, OMALLEY D P, PERKINS S L,et al.Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias[J].Appl Immunohistochem Mol Morphol,2007,15(2):154-159.
[20] BOGDANOVIC G, JAKIMIV D, STOJILJKOVIC B, e t a l . T h e c e l l growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS[J].Med Oncol(Northwood, London, England), 2007, 24(4):419- 424.
[21] SHAHIN O A, RAVANDI F. Myeloid sarcoma[J].Curr Opin Hematol,2020,27(2):88-94.
[22] KAWAMOTO K, MIYOSHI H, YOSHIDA N, et al.Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients[J]. Am J Surg Pathol,2016,40(11):1473-1483.
[23] 董振坤.97 例髓系肉瘤临床特征及预后因素分析[D]. 郑州: 郑州大学,2019. DONG Zhenkun. Clinical characteristics and prognostic factors analysis of myeloid sarcoma: a report of 97 cases[D]. Zhengzhou: Zhengzhou University, 2019.
[24] MAGDY M, ABDEL K N, ELDESSOUKI I, et al. Myeloid Sarcoma[J].Oncol Res Treat, 2019, 42(4):224-229.
[25] HASHII Y, OKUDA T, OHTA H, et al.Pediatric myeloid/NK cell precursor lymphoma/leukemia expressing T/NK immunophenotype markers[J].Int J Hematol,2010,91(3):525-529.
[26] 杜汉芳, 许海军, 赵颖. 抗MPO、抗GBM、抗 PR3、抗Ku 抗体诊断自身免疫性溶血性贫血的分 析[J]. 国际检验医学杂志,2019,40(1):66-70. DU Hanfang,XU Haijun,ZHAO Ying. Analysis of the clinical value of anti MPO, anti GBM, anti PR3 and anti Ku antibody in autoimmune hemolytic anemia[J]. International Journal of Laboratory Medicine, 2019, 40(1):66-70.
[27] 宋红杰, 马捷. 组织细胞坏死性淋巴结炎的研究进 展[J]. 临床与实验病理学杂志, 2015, 31(5):569-571. SONG Hongjie,MA Jie.Progress histiocytic necrotizing lymphadenitis[J]. Chinese Journal of Clinical and Experimental Pathology, 2015,31(5):569-571.
[28] 柳倩. 探讨组织细胞坏死性淋巴结炎的临床病 理特点和免疫表型[J]. 中国冶金工业医学杂 志,2020,37(1):118-119. LIU Qian.To investigate the clinicopathologic ceatures and immunophenotypes of histiocytic necrotizing lymphadenitis[J].Chinese Medical Journal of Metallurgical Industry,2020, 37(1):118-119.
[29] SUKSWAI N, JUNG H R, AMR S S , e t a l . Immunopathology of Kikuchi-Fujimoto disease: A reappraisal using novel immunohistochemistry markers[J]. Histopathology,2020,77(2):262-274.
[30] 杜华, 师永红, 师迎旭. 组织细胞坏死性淋巴结炎 84 例的临床病理和免疫表型特点[J]. 中华病理学杂 志,2016, 45(2):86-90. DU Hua, SHI Yonghong, SHI Yingxu.Clinicopathologic characteristics and immunophenotypes of histiocytic necrotizing lymphadenitis:an analysis of 84 cases[J]. Chinese Journal of Pathology,2016,45(2):86-90.
[31] TIAN Chen, WANG Yafei, ZHU Lei, et al.Primary bone natural Killer/T cell lymphoma, nasal type without EBV infection: a case report[J].Int J Clin Exp Pathol,2015,8(11):14836-14839.
[32] SUGIYAMA A, KOBAYASHI M, DAIZO A, et al.Diffuse cerebral vasoconstriction in a intravascular lymphoma patient with a high serum MPO-ANCA level[J]. Intern Med, 2017, 56(13):1715-1718.

备注/Memo

备注/Memo:
基金项目：陕西省重点研发计划项目(2019SF-089)；陕西省人民医院领军人才项目（2021LJ-12）。
作者简介：张梦娜(1991-)，女，在读硕士，研究方向：肿瘤病理，E-mail:18391044910@163.com。
通讯作者：李文生(1968-)，男，主任医师，硕士生导师，主要从事肿瘤病理及淋巴瘤病理研究,E-mail:liwensheng263@sohu.com。
更新日期/Last Update: 1900-01-01